Buchumschlag

Sex Differences in the Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta‐Analysis

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Yucheng Yang, Liyun He, Shumeng Han, Na Yang, Yiwen Liu, Xuechen Wang, Ziyi Li, Fan Ping, Lingling Xu, Wei Li, Huabing Zhang, Yuxiu Li
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Journal of Diabetes
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Association of Glucagon‐Like Peptide‐1 Receptor Agonist Use With Risk of Psychiatric Disorders: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
von: Shumeng Han, et al.
Veröffentlicht: (2026)

Efficacy and Safety of Glucagon‐Like Peptide‐1 Receptor Agonists Following Bariatric Surgery: A Systematic Review and Meta‐Analysis
von: Abdur Rafay Bilal, et al.
Veröffentlicht: (2026)

Glucagon‐Like Peptide‐1 Receptor Agonists and Anesthesia—Are We Clearer on the Correct Approach?
von: Zachary Bloomgarden
Veröffentlicht: (2024)

Positive Islet Cell Cytoplasmic Antibody and Long‐Term Use of Lipid‐Lowering Agents Are Positively Correlated With Peripheral Atherosclerosis in Patients With Autoimmune Diabetes: A Cross‐Sectional Study
von: Xinyue Chen, et al.
Veröffentlicht: (2025)

Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
von: Timothy H. Chan, et al.
Veröffentlicht: (2026)

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study
von: Arvid Engström, et al.
Veröffentlicht: (2026)

Effects of Glucagon‐Like Peptide‐1 Receptor Agonist on Bone Mineral Density and Bone Turnover Markers: A Meta‐Analysis
von: Hee‐Ju Kim, et al.
Veröffentlicht: (2024)

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials
von: Ayah Abulehia, et al.
Veröffentlicht: (2026)

Effect of Glucagon‐Like Peptide‐1 Receptor Agonists on Renal and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Mellitus: A Retrospective Study
von: Daniel Yuan, et al.
Veröffentlicht: (2025)

Long‐Term Glucagon‐Like Peptide 1 Receptor Agonist Use Is Not Associated With Increased Risk of Thyroid Cancer in Adults With Type 2 Diabetes
von: Rena Pollack, et al.
Veröffentlicht: (2025)

Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta‐Analysis of Clinical Trials
von: Celina R. Andonie, et al.
Veröffentlicht: (2025)

Kidney Outcomes With Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Glucose‐Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta‐Analysis of Real‐World Data
von: Alisa Fishkin, et al.
Veröffentlicht: (2025)

Comparison of Sodium‐Glucose Cotransporter 2 Inhibitors Versus Glucagon‐Like Peptide‐1 Receptor Agonists and Risks of Osteoarthritis and Arthroplasty in Patients With Type 2 Diabetes Mellitus: A Propensity Score‐Matched Cohorts Retrospective Study
von: Yu‐Chi Su, et al.
Veröffentlicht: (2025)

GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs
von: Jirawan Vienghirun, et al.
Veröffentlicht: (2026)

Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study
von: Takeshi Miyatsuka, et al.
Veröffentlicht: (2026)

An Update on GLP‐1 Receptor Agonists
von: Zachary Bloomgarden
Veröffentlicht: (2025)

Weight Loss Outcomes Between GLP ‐1 Receptor Agonists and Bariatric Surgery in Adults With Obesity: A Systematic Review, Meta‐Analysis and Meta‐Regression
von: Muhammad Tahir, et al.
Veröffentlicht: (2026)

Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials
von: Yue Yin, et al.
Veröffentlicht: (2025)

GLP ‐1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta‐Analysis
von: Cynthia F. X. C. A. Silva, et al.
Veröffentlicht: (2026)

Efficacy of a Comprehensive Weight Reduction Intervention in Male Adolescents With Different FTO Genotypes
von: Zahra Roumi, et al.
Veröffentlicht: (2024)

Impact of GLP ‐1 Receptor Agonist Discontinuation on Liver‐Related Parameters: A Systematic Review and Meta‐Analysis
von: Matheus Souza, et al.
Veröffentlicht: (2026)

Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes
von: Zhimin Xu, et al.
Veröffentlicht: (2024)

GLP ‐1 Receptor Agonists and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Target Trial Emulation
von: Haisheng Wu, et al.
Veröffentlicht: (2026)

Interpreting Pregnancy Risk After GLP ‐1 Receptor Agonists Discontinuation
von: Roberta Scairati, et al.
Veröffentlicht: (2026)

Plantar Tissue Characteristics in People With Diabetes With and Without Peripheral Neuropathy: A Novel Explanatory Model for DPN Risk Assessment
von: Yiming Li, et al.
Veröffentlicht: (2025)

Efficacy of Tirzepatide Dual GIP / GLP ‐1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real‐World Propensity Score‐Matched Study
von: Ahmed Y. Azzam, et al.
Veröffentlicht: (2025)

Association of GLP ‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program
von: Inyoung Hwang, et al.
Veröffentlicht: (2026)

Effects of GLP‐1 Receptor Agonists on Paediatric Population in a Real World Setting
von: A. G. Barajas, et al.
Veröffentlicht: (2025)

The Gastrointestinal Safety of Orforglipron, a GLP ‐1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta‐Analysis of Randomized Controlled Trials
von: Ahmed W. Hageen, et al.
Veröffentlicht: (2026)

Efficacy and Safety of Glucagon‐Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta‐Analysis
von: Hassan Raza, et al.
Veröffentlicht: (2026)

RETRACTION : Effects of GLP ‐1 Receptor Agonists on Cognitive Function in Patients With Type 2 Diabetes: A Systematic Review and Meta‐Analysis Based on Randomized Controlled Trials
Veröffentlicht: (2026)

Ensuring the Appropriate Use of Glucagon‐Like Peptide‐1 Receptor Agonists
von: Kenneth Todd Moore, et al.
Veröffentlicht: (2024)

Comparison of GLP‐1 Receptor Agonists, SGLT‐2 Inhibitors, and DPP‐4 Inhibitors as an Add‐On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
von: Sanbao Chai, et al.
Veröffentlicht: (2024)

Impact of Glucagon‐Like Peptide‐1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients
von: Stephanie Shabanowitz, et al.
Veröffentlicht: (2026)

Searching the Crystal Ball for Tailored GLP‐1 Receptor Agonists Treatment in Type 2 Diabetes and Obesity
von: Asia Saturnino, et al.
Veröffentlicht: (2024)

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
von: Richard J. MacIsaac, et al.
Veröffentlicht: (2024)

Association of GLP ‐1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation
von: Tahmid Hussain, et al.
Veröffentlicht: (2026)

Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
von: Hezekiah C. T. Au, et al.
Veröffentlicht: (2026)

Glucagon‐Like Peptide‐1 Receptor Agonists in Obesity‐Induced Respiratory Pathophysiology
von: Melanie Alexis Ruiz, et al.
Veröffentlicht: (2026)

Glucagon‐Like Peptide‐1 Receptor Agonists: Considerations for Treating Preconception Obesity
von: Lauren T. Berube, et al.
Veröffentlicht: (2026)